Corient Private Wealth LLC Has $69.31 Million Position in Pfizer Inc. (NYSE:PFE)

Corient Private Wealth LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 15.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,637,707 shares of the biopharmaceutical company’s stock after selling 484,914 shares during the quarter. Corient Private Wealth LLC’s holdings in Pfizer were worth $69,305,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in PFE. State Street Corp increased its position in Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company’s stock valued at $8,405,930,000 after acquiring an additional 3,405,539 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Pfizer by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock worth $3,392,342,000 after buying an additional 1,855,419 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after buying an additional 6,977,587 shares during the last quarter. Finally, Van ECK Associates Corp increased its stake in shares of Pfizer by 28.5% in the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after buying an additional 4,726,549 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on PFE shares. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, March 12th. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Up 0.5 %

NYSE PFE opened at $25.74 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock’s 50-day moving average is $26.24 and its 200-day moving average is $27.12. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The firm has a market cap of $145.85 billion, a P/E ratio of 18.25, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The business’s revenue was up 24.7% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.